CD274 and non-small cell lung carcinoma: Recently, the interim results of a phase 3 trial (GEMSTONE–301) reported that an anti–PD–L1 antibody (sugemalimab) after chemoradiotherapy prolonged PFS in patients with stage III NSCLC (81).